Published by Coherent Market Insights
Posted on September 15, 2021
The global botulinum toxin market is estimated to be valued at US$ XX million in XXX and is expected to exhibit a CAGR of XX% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. There are about eight types of botulinum toxin, such as type A, type B, type C, type D, type E, type F, type G, and type H. Type A and B are widely used to treat various facial conditions. They are also used to treat various medical conditions, such as dystonia, spasticity, and chronic migraines. Type B is FDA approval for treatment of cervical dystonia.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1518
Moreover, botulinum toxin is extensively used to treat stiffness/spasms or movement disorders (such as cervical dystonia and torticollis), uncontrolled blinking (blepharospasm), crossed eyes (strabismus), and to reduce the cosmetic appearance of wrinkles. This in turn has increased the use of botulinum toxin in several aesthetic procedures and medical applications.
Key Market Drivers:
Increasing use of botulinum toxin in aesthetic procedures and medical applications is expected to aid in the growth of the botulinum toxin market during the forecast period. According to the Aesthetic Society, botulinum toxin has been the #1 non-surgical aesthetic procedure since 1999 and is still growing rapidly. Moreover, in January 2019, Huons Global announced the launch of the new botulinum toxin product in Korea; designed specifically to treat forehead wrinkles.
Moreover, continuous research and development to develop new botulinum toxin treatments is expected to drive growth of the botulinum toxin market. For instance, in July 2020, Croma-Pharma GmbH submitted the drug file of its botulinum toxin product to treat glabellar (frown) lines to the Federal Institute for Drugs and Medical Devices (BfArM).
COVID-19 Impact Analysis:
The pandemic has negatively affected the sales of botulinum toxin products worldwide due to reduced demand in both aesthetic and therapeutic applications. This is attributed to increasing cases of COVID-19 along with nationwide lockdowns and delaying or postponing of the non-essential surgical and non-invasive procedures. However, there is an increasing demand for botulinum toxin in critical care or emergency departments. This in turn is expected to augment the growth of the botulinum toxin market.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1518
Key Takeaways
The botulinum toxin market is expected to exhibit a CAGR of XX % during the forecast period owing to the increasing number of clinical trials to expand therapeutic applications of botulinum toxin. For instance, in July 2021, Daewoong Pharmaceutical announced that the company would speed up the entry into the Chinese market with its botulinum product, Nabota, while releasing the topline results of its phase 3 clinical trials conducted in China.
Among regions, North America is expected to witness significant growth in the botulinum toxin market owing to increasing demand for improved aesthetic appearance and frequent approvals of novel botulinum toxin products in this region. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) approved Evolus Inc.’s cheaper alternative of botulinum toxin for the treatment of frown lines.
Major Players Are: Ipsen group, Allergan Plc., Medytox Inc., Merz GmbH and Co. KGaA, US Worldmed, LLC, Lanzhou Institute of Biological Products Co. Ltd., Revance Therapeutics, Inc., and Daewoong Pharmaceutical Co., Ltd.
Contact Us:
Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Botulinum Toxin Market – product produced by naturally occurring Clostridium botulinum bacteria appeared first on Gatorledger.
The global botulinum toxin market is estimated to be valued at US$ XX million in XXX and is expected to exhibit a CAGR of XX% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. There are about eight types of botulinum toxin, such as type A, type B, type C, type D, type E, type F, type G, and type H. Type A and B are widely used to treat various facial conditions. They are also used to treat various medical conditions, such as dystonia, spasticity, and chronic migraines. Type B is FDA approval for treatment of cervical dystonia.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1518
Moreover, botulinum toxin is extensively used to treat stiffness/spasms or movement disorders (such as cervical dystonia and torticollis), uncontrolled blinking (blepharospasm), crossed eyes (strabismus), and to reduce the cosmetic appearance of wrinkles. This in turn has increased the use of botulinum toxin in several aesthetic procedures and medical applications.
Key Market Drivers:
Increasing use of botulinum toxin in aesthetic procedures and medical applications is expected to aid in the growth of the botulinum toxin market during the forecast period. According to the Aesthetic Society, botulinum toxin has been the #1 non-surgical aesthetic procedure since 1999 and is still growing rapidly. Moreover, in January 2019, Huons Global announced the launch of the new botulinum toxin product in Korea; designed specifically to treat forehead wrinkles.
Moreover, continuous research and development to develop new botulinum toxin treatments is expected to drive growth of the botulinum toxin market. For instance, in July 2020, Croma-Pharma GmbH submitted the drug file of its botulinum toxin product to treat glabellar (frown) lines to the Federal Institute for Drugs and Medical Devices (BfArM).
COVID-19 Impact Analysis:
The pandemic has negatively affected the sales of botulinum toxin products worldwide due to reduced demand in both aesthetic and therapeutic applications. This is attributed to increasing cases of COVID-19 along with nationwide lockdowns and delaying or postponing of the non-essential surgical and non-invasive procedures. However, there is an increasing demand for botulinum toxin in critical care or emergency departments. This in turn is expected to augment the growth of the botulinum toxin market.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1518
Key Takeaways
The botulinum toxin market is expected to exhibit a CAGR of XX % during the forecast period owing to the increasing number of clinical trials to expand therapeutic applications of botulinum toxin. For instance, in July 2021, Daewoong Pharmaceutical announced that the company would speed up the entry into the Chinese market with its botulinum product, Nabota, while releasing the topline results of its phase 3 clinical trials conducted in China.
Among regions, North America is expected to witness significant growth in the botulinum toxin market owing to increasing demand for improved aesthetic appearance and frequent approvals of novel botulinum toxin products in this region. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) approved Evolus Inc.’s cheaper alternative of botulinum toxin for the treatment of frown lines.
Major Players Are: Ipsen group, Allergan Plc., Medytox Inc., Merz GmbH and Co. KGaA, US Worldmed, LLC, Lanzhou Institute of Biological Products Co. Ltd., Revance Therapeutics, Inc., and Daewoong Pharmaceutical Co., Ltd.
Contact Us:
Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Botulinum Toxin Market – product produced by naturally occurring Clostridium botulinum bacteria appeared first on Gatorledger.
Explore more articles in the Research Reports category
